Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > DDR1


Brief Information

Name:Discoidin domain receptor 1
Target Synonym:Epithelial discoidin domain-containing receptor 1,Epithelial discoidin domain receptor 1,CD167 antigen-like family member A,Cell adhesion kinase,Discoidin receptor tyrosine kinase,HGK2,Mammary carcinoma kinase 10,MCK-10,Protein-tyrosine kinase 3A,Protein-tyrosine kinase RTK-6,TRK E,Tyrosine kinase DDR,Tyrosine-protein kinase CAK,CD167a,CD167 Antigen-Like Family Member A,TRKE,RTK6,PTK3A Protein Tyrosine Kinase 3A,PTK3A,NTRK4,Neurotrophic Tyrosine Kinase, Receptor, Type 4,Neuroepithelial Tyrosine
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Loaded Biotinylated Human DDR1, His,Avitag (Cat. No. DD1-H82E9) on SA Biosensor, can bind Native Human Collagen I protein with an affinity constant of 0.603 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).


Loaded Human DDR1, Fc Tag (Cat. No. DD1-H5258) on Protein A Biosensor, can bind Native Human Collagen I protein with an affinity constant of 0.327 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

Synonym Name



Discoidin domain receptor 1 (DDR1) is a member of DDRs, which are members of the receptor tyrosine kinase (RTK). Upon collagen binding, DDR1 undergoes tyrosine autophosphorylation, which consequently triggers downstream genetic and cellular pathways and plays critical roles in the regulation of cellular morphogenesis, differentiation, proliferation, adhesion, migration, and invasion. Research shows that DDR1 is closely related to various human diseases including cancer, fibrosis, atherosclerosis, and other inflammatory disorders. New generation DDR1 inhibitors targeting the allosteric sites outside of the canonical ATP-binding pocket or extracellular domain (allosteric inhibitors) may offer a new opportunity for selective DDR1 inhibition therapy development.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
APL-102 APL-102; CBT-102 Phase 1 Clinical Apollomics Inc Solid tumours Details
PRTH-101 PRTH-101 Phase 1 Clinical The George Washington University Milken Institute School Of Public Health (Gwu), Parthenon Therapeutics Inc Solid tumours; Neoplasms Details
ICP-033 ICP-033 Phase 1 Clinical Beijing Innocare Pharma Tech Co Ltd Solid tumours Details
AVI-4015 AVI-4015 Phase 1 Clinical Avixgen Dry Eye Syndromes Details
AGX-0073 AGX-0073 Phase 1 Clinical Shanghai Aojian Biological Technology Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message